Metoject

Methotrexate, the active ingredient in Metoject, is an antimetabolite presented as a sterile injectable solution for intramuscular, intravenous, subcutaneous use. It is employed to treat autoimmune disorders and certain malignancies in adults and children. GNH USA supplies Metoject as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Methotrexate is an antimetabolite used across several disease families, primarily autoimmune and oncologic conditions.

Rheumatoid arthritis: reduces disease activity and joint inflammation. Psoriasis: slows skin cell proliferation and improves lesions. Acute lymphoblastic leukemia: interferes with leukemic cell DNA synthesis. Non‑Hodgkin lymphoma: inhibits growth of malignant lymphocytes. Gestational trophoblastic disease: promotes resolution of trophoblastic tissue.

Adverse reactions can vary from mild to severe and should be monitored during therapy.

Common Side Effects: - Nausea or vomiting. - Fatigue and malaise. - Mucositis or mouth sores. - Mild elevation of liver enzymes.

Serious or Rare Side Effects: - Bone marrow suppression leading to pancytopenia. - Severe hepatotoxicity or fibrosis. - Pulmonary toxicity, including interstitial pneumonitis. - Acute renal failure or nephrotoxicity. - Anaphylactic or severe hypersensitivity reactions.

Methotrexate requires careful monitoring and specific safety measures before and during treatment.

Pregnancy: contraindicated (Category X) due to high teratogenic risk. Renal function: assess baseline and monitor regularly; dose adjustment may be needed. Liver function: perform periodic liver enzyme tests to detect hepatotoxicity. Hematologic monitoring: conduct frequent blood counts to identify myelosuppression. Store at ambient temperature: keep in original container, protect from light and moisture.

Methotrexate interacts with several medicines that can alter its efficacy or increase toxicity.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase risk of renal toxicity. - Penicillins and other β‑lactam antibiotics: may enhance methotrexate plasma levels. - Sulfonamides and trimethoprim: potentiate bone marrow suppression.

Moderate Interactions (Monitor Closely): - Azathioprine or other immunosuppressants: additive myelosuppressive effect. - Warfarin: may increase anticoagulant effect, requiring INR monitoring.